Management Team

alternate text

Paul Lammers, M.D., M.S.

President & Chief Executive Officer

Dr. Paul Lammers is President and CEO of Mirna Therapeutics. Prior to joining Mirna Therapeutics, Dr. Lammers was most recently president of Repros Therapeutics. Dr. Lammers served for 6 years as the CMO for EMD Serono Inc. and began his career with Organon spending 8 years in the commercial and clinical operations in Europe and the US. He also served 4 years as Senior Vice President of clinical and regulatory affairs at Zonagen. Dr. Lammers obtained his Medical Degree and Masters of Science degree from the Catholic University in Nijmegen, The Netherlands, and moved with his family to the US in 1992.

alternate text

Jon Irvin

Chief Financial Officer

Jon Irvin is the Chief Financial Officer of Mirna Therapeutics, Inc. Mr. Irvin has over 30 years of experience in the life science, medical, software and high tech industries. He has served as CFO at companies including Voxpath Networks, Reddwerks Corporation, Esoterix, and Topaz Technologies in Austin, Texas, and BioNumerik Pharmaceuticals in San Antonio Texas. He started his career in public accounting, working for Ernst & Young in San Antonio, Texas, Price Waterhouse in Newport Beach, California, and spent eight years with the life science group for Ernst & Young in Palo Alto. Mr. Irvin is a graduate of the University of Illinois with degree in Accounting.

alternate text

Sinil Kim, M.D.

Vice President Oncology & Chief Medical Officer

Dr. Sinil Kim is the Chief Medical Officer and VP of Oncology at Mirna Therapeutics, Inc. Dr. Kim received his B.S. in Chemistry and M.D. from the University of Washington, completed his Hematology/Oncology post-doctoral fellowship at University of California San Diego and served as an Associate Professor. He co-founded DepoTech Corp to work on DepoCyt, DepoDur and Exparel, and subsequently moved to Bristol-Myers Squibb to join the Erbitux BLA filing team. Most recently, Dr. Kim served as the Global Clinical Leader for Inlyta and Torisel at Pfizer, Inc.

alternate text

David Brown, Ph.D.

Director, Discovery and in vivo Research

Dr. David Brown is Director of Drug Discovery and in vivo Research at Mirna Therapeutics. Dr. Brown was the Director of Discovery at Asuragen, Inc. where he oversaw efforts to identify diagnostic and therapeutic applications for miRNAs from 2006 to 2008. From 1996 to 2006, Dr. Brown served in the R&D Department at Ambion, Inc. and developed research products for the life sciences market. Dr. Brown received his Ph.D. in Molecular Biology from the University of Colorado and currently serves as an Adjunct Professor at the University of Texas MD Anderson Cancer Center.

alternate text

Andreas Bader, Ph.D., M.S.

Director, Analytical and External Research

Dr. Andreas Bader is Director of Analytical and External Research at Mirna Therapeutics. He served for 2 years at Asuragen as the Project Lead of the miRNA therapeutics program. Prior to joining Asuragen in 2006, Dr. Bader completed his post-doctoral training at The Scripps Research Institute, La Jolla, California, where he also held a junior faculty position. Dr. Bader received his M.S. degree in Biology in 1997 and his Ph.D. in Biochemistry in 2000 from the University of Innsbruck, Austria. Since the beginning of his career, Dr. Bader has been focusing on molecular mechanisms of cancer and the identification of novel cancer drug targets.

alternate text

Jay Stoudemire, Ph.D.

Vice President Pre-clinical Development, Regulatory & Quality Assurance

Dr. Stoudemire received his Ph.D. in Microbiology from the University of Miami and he completed a postdoctoral fellowship in the Cardiovascular Research Institute at the University of California San Francisco. He has held positions at Genentech, Ascenta Therapeutics, Chugai-Roche Pharmaceuticals, Cytel, Genetics Institute, and Xoma, with responsibility for the pharmacokinetic and toxicological evaluations of a range of small molecules and biologics including cytokines, growth and hematopoietic factors, monoclonal antibodies, and pro-apoptotic therapeutics.

alternate text

Neil Leatherbury

Director, Pharmaceutical Development

Mr. Leatherbury is the Director of Pharmaceutical Development. Prior to joining Mirna, he was Director of Product Development at Azaya Therapeutics, developing liposomal delivery systems for water insoluble drugs. He also worked as a Senior Engineer at OsteoBiologics, developing bio-absorbable tissue engineering implants primarily for orthopedic indications. His main focus is on product development of early-stage therapies and their rapid translation from lab bench to the clinic. He holds a Bachelor’s degree in Chemical Engineering from Rice University, and a Master’s degree in Management of Technology from the University of Texas at San Antonio.

Mirna Therapeutics Announces Interim Phase 1 Safety Data on Lead Product Candidate MRX34 at AACR Annual Meeting

Read More

Mirna Therapeutics Appoints Casi DeYoung as Chief Business Officer

Read More

Mirna Therapeutics Announces Scientific Publication that Suggests Enhanced Potency of Lead Therapeutic MicroRNA in Combination with FDA Approved Lung Cancer Drug

Read More

Contact info:

Mirna Therapeutics Inc.

2150 Woodward St., Suite 100 | Austin, TX 78744 | USA

1-512-681-5201 fax

For inquiries please use the following contacts:


Business Development: